Receiving Quadrivalent Vaccine Will Not Negatively Affect Efficacy
If WHO recommends trivalent vaccine for 2026 but your patient receives quadrivalent instead, this will not reduce efficacy—in fact, it provides broader protection. The quadrivalent vaccine contains all three antigens present in the trivalent formulation plus an additional influenza B strain from the second lineage 1.
Understanding the Vaccine Composition
What's the Difference?
Trivalent vaccines contain:
- One A(H1N1) strain
- One A(H3N2) strain
- One B strain (from either Victoria or Yamagata lineage)
Quadrivalent vaccines contain:
- The same three strains as trivalent PLUS
- A second B strain from the other lineage 1
The quadrivalent formulation is essentially the trivalent vaccine with one additional protective component—nothing is removed or reduced.
Evidence on Comparative Effectiveness
Real-World Performance
Recent evidence demonstrates that quadrivalent vaccines provide at least equivalent and often superior protection compared to trivalent formulations:
In seasons with high influenza B activity, quadrivalent vaccines showed 8-11% lower odds of hospitalization and 16% lower odds of emergency department visits compared to trivalent vaccines 2
Overall effectiveness against influenza B was 53% for quadrivalent versus 45% for trivalent vaccines, with the advantage most pronounced when the circulating B lineage didn't match the trivalent formulation 3
A 2025 systematic review confirmed quadrivalent vaccines provide superior immunogenicity across all age groups, particularly during B-lineage mismatches, with comparable safety profiles 4
Why Quadrivalent May Be Better
The key advantage is protection against both influenza B lineages (Victoria and Yamagata). Since these lineages provide only limited cross-protection and it's difficult to predict which will predominate, the quadrivalent vaccine offers broader coverage 1. Modeling suggests this could prevent an additional 2,200-970,000 cases, 14-8,200 hospitalizations, and 1-485 deaths annually 1.
Safety Profile
The safety of quadrivalent vaccines is equivalent to trivalent formulations 1, 4. Studies comparing the two showed:
- Similar rates of adverse reactions overall
- Slightly higher rates of local injection site pain in some populations, but no increase in serious adverse events
- No immune interference between the four strains 1
Clinical Bottom Line
Administer the quadrivalent vaccine without hesitation. Your patient will receive:
- Full protection against all three strains in the WHO-recommended trivalent formulation
- Bonus protection against the additional B lineage
- No reduction in effectiveness for any component
- No increased safety concerns
Common Pitfall to Avoid
Do not delay vaccination waiting for a specific formulation. The most important factor is timely vaccination before influenza season peaks. Any licensed, age-appropriate influenza vaccine should be administered when available 5, 6.
Note on 2025-2026 Season Context
The WHO's shift toward trivalent recommendations reflects the global disappearance of the B/Yamagata lineage since 2020 7. However, if quadrivalent vaccines remain available in your region, they remain fully appropriate and effective, as they still contain all recommended strains plus the additional (now rarely circulating) B lineage 6, 8.